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Aims/hypothesis Our aims were to compare osteoclastic activity between patients
with acute Charcot’s osteoarthropathy and diabetic and healthy controls, and to
determine the effect of the receptor activator of nuclear factor-kappaB ligand
(RANKL) and its decoy receptor osteoprotegerin (OPG). Methods Peripheral blood
monocytes isolated from nine diabetic Charcot patients, eight diabetic control and
eight healthy control participants were cultured in the presence of macrophage-
colony stimulating factor (M-CSF) alone, M-CSF and RANKL, and also M-CSF and
RANKL with excess concentrations of OPG. Osteoclast formation was assessed by
expression of tartrate-resistant acid phosphatase on glass coverslips and resorption
on dentine slices. Results In cultures with M-CSF, there was a significant increase in
osteoclast formation in Charcot patients compared with healthy and diabetic control
participants (p = 0.008). A significant increase in bone resorption was also seen in
the former, compared with healthy and diabetic control participants (p < 0.0001).
The addition of RANKL to the cultures with M-CSF led to marked increase in
osteoclastic resorption in Charcot (from 0.264 ± 0.06% to 41.6 ± 8.1%, p < 0.0001)
and diabetic control (0.000 ± 0.00% to 14.2 ± 16.5%, p < 0.0001) patients, and also
in healthy control participants (0.004 ± 0.01% to 10.5 ± 1.9%, p < 0.0001). Although
the addition of OPG to cultures with M-CSF and RANKL led to a marked reduction of
resorption in Charcot patients (41.6 ± 8.1% to 5.9 ± 2.4%, p = 0.001), this
suppression was not as complete as in diabetic control patients (14.2 ± 16.5% to
0.45 ± 0.31%, p = 0.001) and in healthy control participants (from 10.5 ± 1.9% to
0.00 ± 0.00%, p < 0.0001). Conclusions/interpretation These results indicate that
RANKL-mediated osteoclastic resorption occurs in acute Charcot’s osteoarthropathy.
However, the incomplete inhibition of RANKL after addition of OPG also suggests the






















Publié sur Okina (http://okina.univ-angers.fr)
